• Sponsored Content

BPI Contributor

February 27, 2024

30 Min View
908 Devices
908 Devices

Date: Feb 27, 2024

Duration: 30 Min

This webcast features: Prasanna Srinivasan, PhD, Research Scientist, Center for Biomedical Innovation, MIT & Graziella Piras, PhD, Senior Director, Strategic Marketing, 908 Devices.

Gene therapy holds incredible potential to transform healthcare. The adeno-associated virus (AAV) produced through the triple-plasmid transfection method in HEK 293 cells is a widely utilized viral vector (VV) due to its non-pathogenic nature, broad tropism, ability to engineer its properties, and established manufacturing platforms. Despite the method's established status, challenges persist in achieving a high VV titer and a favorable ratio of full to empty capsids.

In this webcast, 908 Devices explores approaches to address these technological gaps. This involves utilizing engineered devices, mechanistic model predictions, high-throughput metabolic screening, and molecular biology techniques to facilitate cost-effective and scalable vector production at a personalized level.

The presentation by Prasanna Srinivasan, PhD and Graziella Piras, PhD will delve into strategies employing rapid and straightforward analytical tools at the point of use to swiftly assess key nutrient consumption, providing feedback to optimize feed and supplement addition strategies. Additionally, the use of continuous culture for rAAV production from the triple-plasmid transfection HEK293 system will be discussed.

Key Takeaways:

  • Use of model-driven approach to design, predict, test, and optimize VV production processes.

  • Benefit of using high-throughput metabolite screening to optimize AAV production using triple transfection method.

  • Scale up and transfer to a continuous process at a bioreactor scale.

You May Also Like